GlassScriptPhysician profile
Lee A Colyar
NPI 1386626166
$2,656.86
in general payments reported to CMS, 2019-2025
30 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $114 · 2021: $80.15 · 2022: $200 · 2023: $518 · 2024: $865 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.65 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $412.62 | 2023-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $266.80 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Lilly USA, LLC | $248.21 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $140.27 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.75 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.67 | 2021-2024 | Ofev, Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $110.33 | 2019-2024 | Arexvy, Shingrix |
| Astellas Pharma US INC | $92.71 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $58.18 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $56.60 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $53.56 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $53.41 | 2023 | Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $47.98 | 2022-2023 | |
| Amarin Pharma, INC. | $46.07 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $44.09 | 2019-2020 | |
| Dynavax Technologies Corporation | $41.40 | 2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $39.68 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $37.39 | 2019-2022 | |
| Esperion Therapeutics, INC. | $29.64 | 2022-2023 | Nexletol |
| Ucb, INC. | $29.45 | 2024 | Briviact |
| Dexcom, INC. | $26.81 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $24.36 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $23.04 | 2023 | Pyrukynd |
| Otsuka America Pharmaceutical, INC. | $17.94 | 2019 | |
| Sumitomo Pharma America, INC. | $17.36 | 2024 | Gemtesa |
| Shire North American Group INC | $13.71 | 2019 | |
| Sanofi Pasteur INC. | $13.44 | 2019 | |
| Merck Sharp & Dohme LLC | $12.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Colyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.